Tisento Therapeutics

05/29/2026

Bonjour, Angers! Euromit 2026 starts in two days, and we are energized by the prospect of exchanging ideas with others dedicated to improving mitochondrial medicine. Visit us at our booth to learn more about our clinical program in , including our fully enrolled Phase 2b PRIZM study in .

05/26/2026

Next month we’re heading to the United Mitochondrial Disease Foundation’s Mitochondrial Medicine Conference! Every year, MitoMed brings together leaders in mitochondrial medicine and individuals impacted by mitochondrial diseases. The opportunity for the scientific and medical community to engage directly with patients and families is critical for meaningful innovation – enabling a deeper understanding of their lived experiences and enhancing our personal motivation to advance new treatment options.

Find out more about the conference: https://umdfconference.org/

05/21/2026

We’re pleased that Kristin Lurk has joined our team as executive director of program management! Kristin is a strategic biotech program management leader with deep expertise leading complex, cross-functional drug development programs from preclinical through Phase 3 and pre-commercial launch. She is passionate about continuously learning and bringing clarity and collaboration to every program she has the opportunity to work on. Welcome, Kristin!

05/18/2026

We’re looking forward to Euromit 2026, the largest international conference on mitochondrial pathology, starting later this month! As a Silver Sponsor, we’re proud to support five days of cutting-edge science, clinical updates, networking, and shared commitment to improving outcomes for people affected by mitochondrial diseases. If you’ll be there, visit us at our booth!

View the exciting program and keynote sessions here: https://www.euromit2026.eu/program-overview/

04/30/2026

Check out this Rareatives interview with our VP of Clinical Research, Chad Glasser! The conversation ranges from the complexities of running clinical trials in the space to overcoming challenges with innovative, patient-informed trial designs. The interview also provides perspective on two recent milestones in drug development: the first-ever externally led patient-focused drug development meeting dedicated to MELAS (led by Mitoaction) and the completion of enrollment in our global Phase 2b PRIZM study. Read the interview here: https://rareatives.com/2026/04/29/tisento-therapeutics-chad-glasser-discusses-prizm-trial-zagociguat-development-for-melas/

03/19/2026

We are proud to support as a Silver Sponsor! We look forward to connecting with other scientists, clinicians, and professionals dedicated to advancing the care and understanding of mitochondrial diseases. Visit our booth!

03/16/2026

It’s ! Many can have negative implications for brain health. That’s because the brain requires a massive amount of energy – which can only be sufficiently produced when mitochondria are functioning well.

When we conducted an interview study of individuals living with the rare mitochondrial disease , symptoms related to cognitive function limitations were among those identified as most important to treat. Our PRIZM MELAS study is evaluating the effects of our investigational medicine, zagociguat, on both cognitive symptoms and fatigue.

We’re proud to join the United Mitochondrial Disease Foundation in raising awareness about the connection between mitochondria and brain health!

03/10/2026

Check out this great article highlighting how learnings from are shaping the future of medicine in more common diseases as well. This recent article captured a concept that resonates with us: rare disease research has sharpened trial design discipline and innovation. When populations are small and heterogeneous, endpoints and methods have to be rooted in deep understanding of the disease —because rigor, not scale, drives interpretability. We also recognize the need to collaborate with patients, families, advocates, and other stakeholders around the world as we work toward our shared goal of improving care and treatment for challenging disorders.

Rare disease researchers have long known that viewing each patient as a source of insight rather than a single data point is critical to developing the most effective treatments.

02/28/2026

Today is . We stand with the 300 million people globally who live with a rare disease, including those with rare like .

Read stories of heroes who face their condition with strength and resilience, and who are dedicated to educating the public: https://www.rarediseaseday.org/heroes/

02/23/2026

In the lead-up to , we join the global call for action to ensure that people living with a have equal opportunities in education, work, and social activities, as well as fair access to healthcare, diagnosis, and treatment.

There are more than 6,000 rare diseases, many of which are chronic, progressive, degenerative, disabling, and life-threatening. Due to the rarity of each disease, expertise and information are scarce. In health and support systems designed for common diseases, those with a rare disease often face inequities. Learn more in the global toolkit:https://download2.rarediseaseday.org/2025/campaign_materials/Toolkits/Equity_Toolkit.pdf

We are honored to be part of the rare disease community and feel great responsibility to develop treatments to address what matters most, beginning with rare like .

The Official Campaign Video of Rare Disease Day 2026- Learn more and get involved!👉 https://www.rarediseaseday.org/